Disease modifying therapies for alzheimer's disease targeting a β oligomers: Implications for therapeutic mechanisms

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Matsubara, Etsuro ^a   Takamura, Ayumi ^a,b   Okamoto, Yasuhide ^c   Oono, Hideto ^a   Nakata, Takashi ^a   Wakasaya, Yasuhito ^a   Kawarabayashi, Takeshi ^a   Shoji, Mikio ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b Shin yurigaoka General Hospital   (Japan)

^c Immunas Pharma Incorporation   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BAPINEUZUMAB; MONOCLONAL 72D9; MONOCLONAL ANTIBODY; NEUROPROTECTIVE AGENT; SOLANEZUMAB; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; ANTIBODY LABELING; ARTICLE; BRAIN PROTECTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; HUMAN; NEUROPROTECTION; BRAIN; CELL LINE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROTEIN QUATERNARY STRUCTURE; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; TOXICITY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIBODIES, MONOCLONAL; BRAIN; CELL LINE; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN STRUCTURE, QUATERNARY;

EID: 84884241457     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/984041     Document Type: Article

References (36)

1. Hardy J. A., Higgins G. A., Alzheimer's disease: the amyloid cascade hypothesis. Science 1992 256 5054 184 185 2-s2.0-0026597063
2. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guldo T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P., Immunization with amyloid- β attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature 1999 400 6740 173 177 2-s2.0-0033536163 10.1038/22124
3. Kotilinek L. A., Bacskai B., Westerman M., Kawarabayashi T., Younkin L., Hyman B. T., Younkin S., Ashe K. H., Reversible memory loss in a mouse transgenic model of Alzheimer's disease. Journal of Neuroscience 2002 22 15 6331 6335 2-s2.0-0036703483
4. Bard F., Cannon C., Barbour R., Burke R.-L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., Yednock T., Peripherally administered antibodies against amyloid β -peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Medicine 2000 6 8 916 919 2-s2.0-0033835996 10.1038/78682
5. Bard F., Barbour R., Cannon C., Carretto R., Fox M., Games D., Guido T., Hoenow K., Hu K., Johnson-Wood K., Khan K., Kholodenko D., Lee C., Lee M., Motter R., Nguyen M., Reed A., Schenk D., Tang P., Vasquez N., Seubert P., Yednock T., Epitope and isotype specificities of antibodies to β -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proceedings of the National Academy of Sciences of the United States of America 2003 100 4 2023 2028 2-s2.0-0037452779 10.1073/pnas.0436286100
6. Selkoe D. J., Alzheimer's disease is a synaptic failure. Science 2002 298 5594 789 791 2-s2.0-0037174618 10.1126/science.1074069
7. Haass C., Selkoe D. J., Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β -peptide. Nature Reviews Molecular Cell Biology 2007 8 2 101 112 2-s2.0-33847662852 10.1038/nrm2101
8. Lambert M. P., Barlow A. K., Chromy B. A., Edwards C., Freed R., Liosatos M., Morgan T. E., Rozovsky I., Trommer B., Viola K. L., Wals P., Zhang C., Finch C. E., Krafft G. A., Klein W. L., Diffusible, nonfibrillar ligands derived from A β 1-42 are potent central nervous system neurotoxins. Proceedings of the National Academy of Sciences of the United States of America 1998 95 11 6448 6453 2-s2.0-11544279355
9. Kayed R., Head E., Thompson J. L., McIntire T. M., Milton S. C., Cotman C. W., Glabel C. G., Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003 300 5618 486 489 2-s2.0-0242668337 10.1126/science.1079469
10. Akiyama H., Barger S., Bamum S., Inflammation and Alzheimer's disease. Neurobiology of Aging 2000 21 3 383 421
11. Gong Y., Chang L., Viola K. L., Lacor P. N., Lambert M. P., Finch C. E., Krafft G. A., Klein W. L., Alzheimer's disease-affected brain: presence of oligomeric A β ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proceedings of the National Academy of Sciences of the United States of America 2003 100 18 10417 10422 2-s2.0-0042838303 10.1073/pnas. 1834302100
12. Hoshi M., Sato M., Matsumoto S., Noguchi A., Yasutake K., Yoshida N., Sato K., Spherical aggregates of β -amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3 β Proceedings of the National Academy of Sciences of the United States of America 2003 100 11 6370 6375 2-s2.0-0037975676 10.1073/pnas.1237107100
13. Lacor P. N., Buniel M. C., Chang L., Fernandez S. J., Gong Y., Viola K. L., Lambert M. P., Velasco P. T., Bigio E. H., Finch C. E., Krafft G. A., Klein W. L., Synaptic targeting by Alzheimer's-related amyloid β oligomers. Journal of Neuroscience 2004 24 45 10191 10200 2-s2.0-20844458090 10.1523/JNEUROSCI.3432-04.2004
14. Cleary J. P., Walsh D. M., Hofmeister J. J., Shankar G. M., Kuskowski M. A., Selkoe D. J., Ashe K. H., Natural oligomers of the amyloid- β protein specifically disrupt cognitive function. Nature Neuroscience 2005 8 1 79 84 2-s2.0-16644379264 10.1038/nn1372
15. Lacor P. N., Buniel M. C., Furlow P. W., Clemente A. S., Velasco P. T., Wood M., Viola K. L., Klein W. L., A β oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. Journal of Neuroscience 2007 27 4 796 807 2-s2.0-33846633336 10.1523/JNEUROSCI.3501-06.2007
16. Takamura A., Okamoto Y., Kawarabayashi T., Yokoseki T., Shibata M., Mouri A., Nabeshima T., Sun H., Abe K., Urisu T., Yamamoto N., Shoji M., Yanagisawa K., Michikawa M., Matsubara E., Extracellular and intraneuronal HMW-AbetaOs represent a molecular basis of memory loss in Alzheimer's disease model mouse. Molecular Neurodegeneration 2011 6 1, article 20 2-s2.0-79952196722 10.1186/1750-1326-6-20
17. Takamura A., Sato Y., Watabe D., Sortilin is required for toxic action of A β oligomers (A β Os): extracellular A β Os triggers apoptosis, and intracellular A β Os impair degradation pathways. Life Sciences 2012 10 23-24 1177 1186
18. Nicolll J. A. R., Wilkinson D., Holmes C., Steart P., Markham H., Weller R. O., Neuropathology of human Alzheimer disease after immunization with amyloid- β peptide: a case report. Nature Medicine 2003 9 4 448 452 2-s2.0-0037393454 10.1038/nm840
19. DeMattos R. B., Bales K. R., Cummins D. J., Dodart J.-C., Paul S. M., Holtzman D. M., Peripheral anti-A β antibody alters CNS and plasma A β clearance and decreases brain A β burden in a mouse model of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2001 98 15 8850 8855 2-s2.0-0035902619 10.1073/pnas.151261398
20. Deane R., Sagare A., Hamm K., Parisi M., LaRue B., Guo H., Wu Z., Holtzman D. M., Zlokovic B. V., IgG-assisted age-dependent clearance of Alzheimer's amyloid β peptide by the blood-brain barrier neonatal Fc receptor. Journal of Neuroscience 2005 25 50 11495 11503 2-s2.0-30844472909 10.1523/JNEUROSCI.3697-05.2005
21. Solomon B., Koppel R., Frankel D., Hanan-Aharon E., Disaggregation of Alzheimer β -amyloid by site-directed mAb. Proceedings of the National Academy of Sciences of the United States of America 1997 94 8 4109 4112 2-s2.0-0030971789 10.1073/pnas.94.8.4109
22. Yamada K., Yabuki C., Seubert P., Schenk D., Hori Y., Ohtsuki S., Terasaki T., Hashimoto T., Iwatsubo T., A β immunotherapy: intracerebral sequestration of A β by an anti-A β monoclonal antibody 266 with high affinity to soluble A β Journal of Neuroscience 2009 29 36 11393 11398 2-s2.0-70349160023 10.1523/JNEUROSCI.2021-09.2009
23. Matsubara E., Takamura A., Molecular mechanism underlying A β immunotherapy: implications for the toxic action of A β oligomers. Journal of Gerontology & Geriatric Research 2012 S2 001 10.4172/2167-7182.S2-001
24. Yamamoto N., Matsubara E., Maeda S., Minagawa H., Takashima A., Maruyama W., Michikawa M., Yanagisawa K., A ganglioside-induced toxic soluble A β assembly: its enhanced formation from A β bearing the arctic mutation. Journal of Biological Chemistry 2007 282 4 2646 2655 2-s2.0-34047249085 10.1074/jbc.M606202200
25. Robert R., Dolezal O., Waddington L., Hattarki M. K., Cappai R., Masters C. L., Hudson P. J., Wark K. L., Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers. Protein Engineering, Design and Selection 2009 22 3 199 208 2-s2.0-60749093075 10.1093/protein/gzn052
26. Robert R., Streltsov V. A., Newman J., Pearce L. A., Wark K. L., Dolezal O., Germline humanization of a murine A β antibody and crystal structure of the humanized recombinant Fab fragment. Protein Science 2010 19 2 299 308 2-s2.0-76749151115 10.1002/pro.312
27. Marín-Argany M., Rivera-Hernández G., Martí J., Villegas S., An anti-A β (amyloid β) single-chain variable fragment prevents amyloid fibril formation and cytotoxicity by withdrawing A β oligomers from the amyloid pathway. Biochemical Journal 2011 437 1 25 34 2-s2.0-79958773791 10.1042/BJ20101712
28. Morgado I., Wieligmann K., Bereza M., Moleculat basis of β -amyloid oligomer recognition with a conformational antibody fragment. Proceedings of the National Academy of Sciences of the United States of America 2012 109 31 12503 12508
29. Miles L. A., Crespi G. A., Doughty L., Parker M. W., Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a herical conformation. Scientific Reports 2013 3 1302 10.1038/srep01302
30. Lambert M. P., Viola K. L., Chromy B. A., Chang L., Morgan T. E., Yu J., Venton D. L., Krafft G. A., Finch C. E., Klein W. L., Vaccination with soluble A β oligomers generates toxicity-neutralizing antibodies. Journal of Neurochemistry 2001 79 3 595 605 2-s2.0-0034740197 10.1046/j.1471-4159.2001. 00592.x
31. Lee E. B., Leng L. Z., Zhang B., Kwong L., Trojanowski J. Q., Abel T., Lee V. M.-Y., Targeting amyloid- β peptide (A β) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in A β precursor protein (APP) transgenic mice. Journal of Biological Chemistry 2006 281 7 4292 4299 2-s2.0-33645220400 10.1074/jbc.M511018200
32. Lambert M. P., Velasco P. T., Chang L., Viola K. L., Fernandez S., Lacor P. N., Khuon D., Gong Y., Bigio E. H., Shaw P., De Felice F. G., Krafft G. A., Klein W. L., Monoclonal antibodies that target pathological assemblies of A β Journal of Neurochemistry 2007 100 1 23 35 2-s2.0-33846135452 10.1111/j.1471-4159.2006.04157.x
33. Lord A., Gumucio A., Englund H., Sehlin D., Sundquist V. S., Söderberg L., Möller C., Gellerfors P., Lannfelt L., Pettersson F. E., Nilsson L. N. G., An amyloid- β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease. Neurobiology of Disease 2009 36 3 425 434 2-s2.0-70350324013 10.1016/j.nbd.2009.08.007
34. Hillen H., Barghorn S., Striebinger A., Labkovsky B., Müller R., Nimmrich V., Nolte M. W., Perez-Cruz C., Van Der Auwera I., Van Leuven F., Van Gaalen M., Bespalov A. Y., Schoemaker H., Sullivan J. P., Ebert U., Generation and therapeutic efficacy of highly oligomer-specific β -amyloid antibodies. Journal of Neuroscience 2010 30 31 10369 10379 2-s2.0-77955359909 10.1523/JNEUROSCI.5721-09.2010
35. Zhang Y., He J.-S., Wang X., Wang J., Bao F.-X., Pang S.-Y., Yin F., Hu H.-G., Peng X.-L., Sun W.-M., Zheng Y.-P., Hou L.-L., Hong T., Administration of amyloid- β 42 oligomer-specific monoclonal antibody improved memory performance in SAMP8 mice. Journal of Alzheimer's Disease 2011 23 3 551 561 2-s2.0-79951931432 10.3233/JAD-2010-091195
36. Tampellini D., Magrané J., Takahashi R. H., Li F., Lin M. T., Almeida C. G., Gouras G. K., Internalized antibodies to the A β domain of APP reduce neuronal A β and protect against synaptic alterations. Journal of Biological Chemistry 2007 282 26 18895 18906 2-s2.0-34547110577 10.1074/jbc.M700373200